MOULDER LEON O JR 4
4 · Zenas BioPharma, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
Zenas BioPharma (ZBIO) CEO Leon Moulder Receives 500K Option Award
What Happened
Leon O. Moulder Jr., Zenas BioPharma's Chief Executive Officer and a director, was granted a derivative award on June 15, 2026: options covering 500,000 shares of common stock. The grant shows an acquisition price of $0.00 (i.e., an option/award grant rather than a cash purchase). No immediate cash was exchanged and no exercise or sale of underlying shares is reported in this filing.
Key Details
- Transaction date: 2026-06-15; Form 4 filed: 2026-06-17 (timely filing).
- Transaction type/code: Award/Grant (derivative) — 500,000 options; reported price $0.00.
- Vesting (per footnote): 25% vests on June 15, 2027 (first anniversary), remaining shares vest in equal monthly installments over the next 36 months, subject to continued service.
- Shares owned after transaction: Not specified in the provided filing details.
- Filing timeliness: No late filing indicated.
Context
This is a typical executive compensation grant (option award). Because it’s a derivative grant, Moulder does not immediately own the underlying shares — ownership depends on future vesting and any subsequent exercise. The filing does not indicate exercise, sale, or tax-withholding actions tied to this grant.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-06-15+500,000→ 500,000 totalExercise: $18.71Exp: 2036-06-15→ Common Stock (500,000 underlying)
Footnotes (1)
- [F1]The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.